Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions.

68 , 69 This also is consistent with other recent data, 70 which demonstrated a trend toward reduced severe infections with longer dosing intervals, although the difference did not reach statistical significance because only a limited number of patients were included.

also in 111,027 other papers